Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Direxion Daily CSI China Internet Bull 2X Shares (CWEB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Direxion Daily CSI China Internet Bull 2X Shares — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Direxion Daily CSI China Internet Bull 2X Shares trades at $21.66. Which is the better fit depends on your goals.
| ALNY | CWEB | |
|---|---|---|
Market Cap | $39.89B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $491.22 | $60.13 |
52-Week Low | $278.09 | $17.70 |
Enterprise Value | $38.15B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
CWEB trades at $21.93, down 0.63% today, with a bullish technical signal supported by moving averages and ADX. The stock shows neutral oscillators but an overbought short-term RSI. A dividend of $0.09 is scheduled for June 2026. Key support and resistance cluster around $22, indicating a critical price zone for near-term direction.
The outlook hinges on upcoming financial disclosures, as current fundamental metrics are unavailable. Risks include market volatility and reliance on future earnings growth for valuation justification. Investor sentiment remains mixed, awaiting concrete business updates to drive momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Direxion Daily CSI China Internet Bull 2X Shares
CWEB is a leveraged ETF that seeks to provide two times (2x) the daily performance of the CSI China Internet Index. It offers magnified exposure to top Chinese internet companies listed on US and Hong Kong exchanges.
Read more on CWEB →
